• 4D Molecular Therapeutics granted 13 new non-executive employees options to purchase 260,000 common shares on October 13, 2026.
• The awards included 157,600 restricted stock units under the company's amended 2025 Employment Inducement Award Plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610161605PRIMZONEFULLFEED9845158) on October 16, 2026, and is solely responsible for the information contained therein.